Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...

Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...

Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Tango Therapeutics in a ...

(Reuters) - CVS Health (NYSE: CVS) investors will closely examine this week turnaround initiatives spearheaded by new CEO ...

Leerink raised the firm’s price target on Axsome Therapeutics (AXSM) to $150 from $110 and keeps an Outperform rating on the shares. The ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Labcorp Holdings (LH – Research Report) and ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative ...